UBS Group AG lifted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) by 56.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,916 shares of the company’s stock after acquiring an additional 28,099 shares during the period. UBS Group AG’s holdings in Kiniksa Pharmaceuticals International were worth $3,214,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth $44,000. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $31,000. Quantbot Technologies LP bought a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $43,000. Finally, TD Waterhouse Canada Inc. raised its position in shares of Kiniksa Pharmaceuticals International by 1,673.9% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 2,040 shares of the company’s stock worth $79,000 after acquiring an additional 1,925 shares in the last quarter. 53.95% of the stock is owned by institutional investors.
Insider Buying and Selling at Kiniksa Pharmaceuticals International
In other news, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the sale, the director owned 12,546 shares in the company, valued at $628,554.60. This represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer owned 48,565 shares in the company, valued at $2,623,481.30. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.
Kiniksa Pharmaceuticals International Stock Performance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 EPS. As a group, analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on KNSA. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average target price of $60.86.
Read Our Latest Analysis on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
